An Introduction to Glytec's eGMS: The Complete Solution for Best-in-Class Glycemic Management
A webinar developed and presented to CPS Solutions.
Watch the Video Today!
<script src="https://fast.wistia.com/embed/medias/j58dmeutzf.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_j58dmeutzf videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/j58dmeutzf/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" aria-hidden="true" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
Glytec's eGlycemic Management System® (eGMS) is revolutionizing glycemic management by uniting teams around patient safety. Watch the recording of this CPS Solutions webinar to learn how you can ensure best practice for your insulin-requiring patients.
This webinar is hosted by Diabetes Clinical Pharmacist, Stephanie Mason, PharmD, CDCES, with industry updates from Chief Commercial Officer, John Downey. An overview of our eGMS® and a platform demonstration is led by Clinical Partner Solutions Manager, Jonda Dawson, RN, CDCES and Regional Vice President, Andy O'Dell.
John: [00:00:00] Thanks everyone for joining the webinar today, kind of an introduction to Glytec and, uh, our. In class glycemic management solution. We're gonna give everyone just a couple more minutes to join. See a couple of folks, um, coming into the, into the webinar. So if we could just, um, give everyone a minute or two, we'll jump back in.
Alright, let's kick off first. Let me just start by welcoming. Um, all of you and thanking you for taking some time out of your busy schedule to join us today. My name is John Downey. I'm the chief commercial officer at Glytec today. The purpose of this webinar will be to introduce you to our FDA cleared high trust [00:01:00] certified insulin dosing decision support software Glucommander and our eGlycemic Management System platform.
Uh, also EGMS. So along with Glytec unique support approach, we provide the only complete solution for best in class by scenic management.
I think in the next slide, we want to talk really about, you know, CPSs goal of optimizing hospitals, pharmacy performance, yielding cost savings and delivering better quality of care and how it aligns with Glytec drive to support our customers journey to optimal glycemic management. we're proud to form this special relationship with the nation's largest provider or pharmacy support service to hundreds of hospitals and healthcare facilities across the us.
Insulin dosing. We all know has been a significant challenge with new CMS core measures around severe hypo and [00:02:00] hyperglycemia. We believe that the time is now to document and improve insulin dosing practices. We'll take, we will work together to help your customers meet these CMS core measure challenges while greatly improving overall customer outcomes and lowering costs at the same time.
Before we jump into our presentation today, I'd like to introduce you to my colleagues, uh, who are also on the webinar speaking after me. Um, this morning, you'll be hearing from Stephanie Mason, uh, pharm D CDCs, who serves as the diabetes clinical pharmacist at biotech. Stephanie is collaborative working across our clinical team to streamline pharmacy workflows with Glytec EGMS.
Stephanie comes to Glytec with previous experiences, an inpatient diabetes program manager for ECU health, where she oversaw the overall care provided to patients with diabetes during their hospitalization, from admission to discharge. [00:03:00] Also today we have Andy Odel, uh, who's a regional vice president at Glytec.
Andy is a member of our commercial team and is over 20 years of healthcare. It experience helping health systems evaluate and deploy innovative technologies. Finally, last but not least, uh, John Dawson, who is a RN in CDC. Donda is a clinical product solutions manager, and she'll be walking us through the demonstration so that you can see our E GMs in action for over 30 years.
John's nursing career has primarily focused on working with patients with diabetes and since coming to Glytec, she's guided over 30 of Glytec partners through the implementation and delivery process of the Glytec EG. Wrapping up, I will then be sharing some more information on how Glytec and CPS can work together.
And what a relationship with Glytec looks like from a client perspective, but let's get this started. Uh, Stephanie, do you want to take it? [00:04:00]
Stephanie Mason: Yes. Thank you, John. Hello everyone. My name is Stephanie Mason and as John said, I am the diabetes clinical pharmacist here at Glytec. And prior to joining the Glytec team, I served as the inpatient diabetes program manager for, uh, ECU health, um, a large health system in Eastern North Carolina.
And during my time in that role, I really learned a lot about inpatient glycemic management, about how we manage patients with diabetes and hyperglycemia in the hospital. And I also learned quite a bit about how to really create an environment that supports the safe and effective insulin use in the hospital.
You know, as pharmacists, we, we really concern ourselves with medication safety and with helping to optimize the medication regimens that our patients are on. And this certainly holds true when we're talking about insulin in the hospital, we know that insulin is a high alert medication. Uh, insulin historically has [00:05:00] resulted in the most ad of any other high alert medication.
And even if it's not number one today, we know it's certainly, um, in the top five. And so. This conversation today is really important because we need to continue to focus on improving the safety and efficacy of insulin in the hospital. And in my experience, I've really seen hospitals face. Three major barriers to really doing that, to improving the safety and efficacy of insulin in the hospital.
And one of those barriers is a lack of standardization. This is a lack of standardization in workflows, around insulin administration. Uh, it's a lack of standardization in order sets, how providers are actually ordering insulin in. Hospital and, uh, a lack of standardization in insulin dosing protocols, you know, what determines that initial rate of IV insulin or what determines that initial rate of basal insulin.
And so a lack of standardization. [00:06:00] Really increases that risk for, for safety events, uh, to occur. And I know there's a lot of hospitals that really, um, are, are challenged by not having standard practices in place. Another barrier that I've seen is a lack of real time information that healthcare teams can use to inform treatment decisions.
And I'd say, uh, you know, very much the pharmacist is a part of a part of that decision making. Um, when we don't have. That real time information to help inform our treatment decisions. When I think about that in the context of glycemic management, that oftentimes looks like patients riding high. Um, they, there are patients who need to be initiated on insulin therapy, but are not, or there are patients who are on a regimen, but that regimen needs to be intensified.
And so not having real time information that really raises awareness. Of those patients, uh, again, is, is a big barrier. I have seen, uh, [00:07:00] hospitals. And really compromises, um, our limits, I would say healthcare team's ability to really optimize, uh, insulin therapy. And that last barrier is, is metrics. And as John mentioned earlier with the new CMS measures, I think that's doing a great job of starting to raise awareness around inpatient glycemic management and get institutions really focusing more, um, on inpatient glycemic management.
But I know that those CMS measures are only. You know, one piece of the pie. Um, and so hospitals really need metrics to be able to. Here's where the problems are. Um, here's why those problems are occurring. And then here are our efforts that we wanna put into place to improve, um, insulin utilization, but they still need a way to measure the impact of those things.
And so when we talk about. Insulin and really improving the safety and efficacy of insulin in the hospital. We need standardization. We need that real time [00:08:00] information and we need actionable and reliable metrics that our healthcare teams can use to, to improve, um, insulin utilization. And I think that pharmacists are very well positioned to participate in that dialogue and really be a part of these efforts.
And on this, uh, on this slide here, I think this really just reiterates the importance of continuing to focus on, in, on increasing. Um, as I said, the safety and efficacy of insulin and the hospital, um, Is MP did a survey of pharmacists and they asked pharmacists to do two things. The first was they, they had a list of 40 high alert medications and they asked the pharmacist to rank those medications based on their level of concern to cause patient harm.
Um, IV insulin was ranked number one, SubQ number nine, meaning greater concern for the impact that [00:09:00] insulin can have on patients if not used, uh, appropriately. And so I think this just says, you know, we, we need to continue looking at insulin and how we're, how we're using that in the hospital. And the second thing they asked the pharmacist to do.
Was to rank those same medications, but now based on their level of confidence in their hospital's, I'll say protocols, policies that are in place to prevent serious errors and SubQ insulin came in dead last, which means the pharmacist did, did not feel confident in their hospital's approach to, um, to, you know, ensuring the safe use of insulin in the hospital.
And so. Again, this really is to say our conversation today is very relevant. It's very important. We know the use of insulin in the hospital has not decreased. I think we've certainly seen, uh, that with, you know, COVID, um, and the impact on, you know, um, metabolic dysfunction in the hospital. And [00:10:00] so, uh, again, very relevant conversation here and important for our pharmacist to be involved in this conversation.
I think I'll turn it back over to.
Andy O'Dell: Great. Thank you, Stephanie. Uh, hello everyone. Um, as Stephanie mentioned, my name's Andy Odell, uh, I am a of the commercial team here, uh, at Glytec. Uh, I think what we would like to do this point is just have, um, uh, have walk everyone through. A high level overview of sort of who we are as a company, uh, what it is we do.
And, and some of the hospitals we work with. Uh, and, and then once I'm finished, I'll hand it over to Jonda and she'll walk everyone through, uh, an actual demo of our application. Um, as we go through this material, if you do have, uh, questions, please enter those into the Q and a function on your screen. Uh, and we'll be sure to save some time at the end to answer your [00:11:00] questions and provide.
Any additional information that might be helpful. So, um, let's go ahead and jump in. Uh, but, uh, so I'll, I'll kind of kick it off. Um, so Glytec is a eGlycemic management and insulin dosing, uh, decision support software company. Uh, we are actually founded. Back in 2006, by a well known endocrinologist named Dr.
Bruce Bowie alongside our senior VP of research and development, Robbie booth. And when, uh, Dr. Bohi and Robbie, uh, got together and founded the company, they, they really founded it on the belief that if they could help hospitals improve how they titrate insulin in their inpatient care settings, they could dramatically improve patient safety.
And patient outcomes. And that's really been our primary focus over the last 16 years. Fast forward to today. We're now the most used solution in the market, but we're also the most studied solution in the market. In fact, our clients have published over a hundred studies with us to help. [00:12:00] Or the efficacy and the value that our technology can provide.
Um, we're also the only end to end platform in the market. So we not only can address the needs and challenges that our clients have, uh, in their inpatient care settings. We can also address the, the challenges they're having on the outpatient side as well. Uh, and then just from an investment and a growth standpoint, um, obviously, you know, over the years, we've invested heavily into our technology, uh, as well as the people who support both our technology and our clients.
Just to give you an example, you know, two years ago we were roughly 89 employees today. We're just over 120. We've also invested heavily around our innovation efforts. And I'll talk a little bit about that on the next slide. So today we're partnered with over 300 hospitals. Uh, we really work with all shapes and sizes from large health systems and academic medical centers all the way down to 25 bed critical access hospitals.
These hospitals is by. Not only [00:13:00] providing them with our technology, but we also have our own clinical team, which is comprised of, uh, roughly 45, uh, people it's made up of physicians, nurse practitioners, certified diabetes, educators, and pharmacists who really work hand in hand with our clients. Uh, not only to ensure they're leveraging best practices within our technology, but really leveraging best practices for all things like CMIC manage.
Uh, in addition to some of the hospitals we're partnered with, we also have some strategic business partners as well. Uh, we are actually just chosen a few months back by premier GPO as their sole source supplier of eGlycemic management technology. I think the point of bringing this up is, uh, really just a little bit of a, a validation for a lot of the work and effort.
We've over the last few years, um, premier, you know, went out into the marketed pretty much every management technology, so, and wanted to. To their members. And so we do take that sole source [00:14:00] supplier designation, um, seriously. And, and it really is something where we're quite proud of. Um, we also just recently announced a partnership with Roche where we're gonna be putting our, uh, application, uh, uh, uh, as an app on Roche's, um, new point of care, blood glucose meter.
So while we've invested heavily to be able to seamlessly integrate our technology with our clients, EHR. We really look at this as the next step to be able to get our technology even closer to the nurses, you know, basically in the Palm of their hand, uh, to make their lives easier and to make it easier to use our software.
Uh, but this also allows us to get our software even closer to the patient, basically right there at the bedside. Uh, and we, um, look forward to seeing some of the, uh, additional, uh, uh, improvements around, um, patient outcomes there as. Um, not listed on this slide, but something we will be announcing in a few weeks.
We're also integrating our technology with, uh, uh, CGMs. So for those of you who, uh, are, are paying, um, [00:15:00] attention to the FDA, we do expect, uh, the FDA to approve use of continuous glucose monitoring in the inpatient care setting within the next one to two years. And we wanna be sure that we're already prepared when that happens.
Uh, to be able to address the new needs and challenges that are gonna come from that for hospitals who are trying to manage patients who are, uh, obviously, um, leveraging, um, CGM. So, so we'll already have that integration built out and that's also gonna lead to some additional opportunities on the outpatient side, uh, as well, but we'll, we'll be sharing some more information around that in the, uh, the coming weeks.
So that's a little bit about, uh, some of the hospitals we work with, maybe now we can talk about what it is we actually, um, provide them with. So, uh, really at the heart of our eGlycemic Management System, uh, is our application, uh, which we refer to as Glucommander. Uh, so Glucommander is an F. The a clear software solution.
Uh, it uses evidence based algorithms to make dosing recommendations that are [00:16:00] continuously being adjusted and recalculated in real time, based on each patient's changing condition across the continuum of care. Uh, in addition to the core personalized insulin dosing decision support that Glucommander provides, uh, there's a few other key areas of functionality we like to highlight.
And John will go through these during the demo. But we also give our clients access to a whole suite of standard and customized analytics and reporting tools. Um, this is also where our clinical team works very closely with our clients to help them pull their data. Uh, they help them analyze their data and then to ultimately act on that data.
Uh, we also give our clients the ability to perform, um, some surveillance across, uh, all of their facilities and patients who aren't actually on Glucommander. So they can more proactively identify those individuals that are good candidates for an early intervention. So we can actually get them onto Glucommander sooner and get their blood glucose under control instead of waiting until they have some sort of an adverse event first.
Uh, and then lastly, we [00:17:00] give our clients access to a whole suite of workflow and safety alerts. To ensure nurses are checking blood glucoses at the right time and ultimately adjusting insulin titrations in a timely manner. Uh, on the technology side, we are, as I mentioned before, able to seamlessly integrate with our clients EHR.
So there's no need for nurses to toggle between their EHR and Glucommander, they'll be able to access Glucommander right from within the patient's electronic medical record through our smart click functionality. We also are high trust certified and we are a cloud-based application. So there's no need for your it folks to deploy and maintain our application locally on your old server, all that work gonna be done by us in the cloud.
As I mentioned before, we are an FDA cleared software solution. So we have four FDA clearances, uh, one for IV transition, SubQ and outpatient. And I think it is, uh, necessary just to call out the importance of the, the FDA clearance. That's [00:18:00] basically, uh, The FDA validating our safety, the effectiveness and the security of our application.
And while there are other tools in the market, you know, things like rudimentary insulin calculators, and in some cases, folks are, you know, kind of building their own insulin calculators. What a lot of people aren't. Aware of is that even those tools are subject to FDA scrutiny. So if a hospital is going to consider leveraging technology like this, they wanna be sure they're using something with, uh, an FDA clearance so they can, you know, minimize the amount of risk they and their hospital take on.
So at this point, uh, we've talked, uh, a little bit about our technology, uh, and the people who, uh, support that technology. And, and I really do think it's this unique model, uh, that brings together the people process and technology that ultimately enables our clients to strive for improvements in a number of different areas.
Um, first by helping our clients, uh, transition from [00:19:00] paper protocols and sliding scale. They're able to dramatically improve patient safety and outcomes. Ultimately it's those improved clinical outcomes that result in cost savings for the hospital, which I think is fair to say most hospitals are trying to find ways to do that.
We also allow our clients to introduce some scale and consistency across their units and facilities to ensure not only that providers are ordering insulin appropriately, but ultimately that nurses are then administering that insulin appropriately. Um, we also understand that it's really challenging to be a clinician right now.
We realize folks are spread incredibly thin and have, uh, more things to do in a day than time to do them. So we are also going to provide, uh, the safety guard rails, guided workflows and education. To help clinicians feel confident that they can provide, uh, effective and, uh, safe care for their patients, with [00:20:00] our technology.
Uh, and then lastly, we understand that it can sometimes be a challenge to overcome clinical inertia. Uh, I mean, we totally get it. If, if folks have been doing something a certain way for, for many, many years, um, it can be hard to change. So, you know, we'll be there every step of the way, providing ongoing consultation, uh, additional services.
Uh, and support to ensure we can help our clients drive adoption across their facilities, uh, and, and, and really make sure that they're gonna be able to get the benefit and the return on their investment that they expect to get. But also that we would expect them to, uh, achieve as well. So now let's talk just a little bit about what it is we're actually helping our clients solve for, with our technology.
And I'm not sure if this, uh, really looks familiar, uh, to you all or not, but this is basically what it looks like when we try to manage our patients, play glucose with some of the, uh, outdated methodologies. Things like paper protocols and sliding scale. Um, so while we might be successful in bringing our patient's blood glucose [00:21:00] down, uh, the real challenge though, is getting them into range and keeping them in range.
Uh, we know from numerous studies, the less time a patient spends in range, the more time they're gonna spend in the hospital. The less healthy they're gonna be. And the more they're going to cost a hospital to care for them. In addition to the traditional challenges, as we've mentioned earlier, we now have some, uh, new encouragement from CMS, uh, where they just recently announced two new quality reporting measures around severe hyperglycemia, uh, and severe hyperglycemia.
And really, I think now that this is on CMSs, radars is really telling hospitals that, you know, one. CMS thinks, you know, hospitals should be able to report on these, uh, measures. Uh, but two, they think hospitals should be able to not only manage, but quite frankly, prevent them from occurring in their hospital.
So if hospitals are going to participate effectively in these new quality measures, it's really imperative that they. Uh, [00:22:00] start now, uh, planning and strategizing on getting the right technology in place. Not only to have the data they need, uh, to send, but also to ensure they have their hypo and hyper rates where they need to be.
Uh, ideally before the reporting period starts, uh, this coming January. But then, uh, definitely before the following January, when this data will be made public, uh, for all to. So, what does it, uh, look like once a hospital has deployed Glucommander and what are some of the results that are, that are typical?
And when we talk about results, we kind of talk about 'em in three different buckets. Uh, if you will. So we like to look at what are the improvements from, uh, clinical outcome standpoint. Uh, we also like to look at what are the benefits from a cost savings standpoint. And then lastly, what are some of the time saving, uh, and efficiency improvements we can provide clinicians.
And so if we just sort of take the, the first bucket, if you will, uh, in terms of improved clinical outcomes, these are just a handful of results that were pulled [00:23:00] from, you know, the a hundred plus studies that have, uh, been published. And so one, uh, came from advent health where they were able to reduce their preventable, severe hypo, adverse drug events by 62%.
Um, at Sentara, they were able to. Their, uh, median time to target for DKA down to five hours on average. And I'm sure as we all know, DKA is one of the more challenging, um, patient types to manage. Um, we had a, a broader study that looked across nine hospitals, specifically focused on SubQ. Showed 62% of BGS were actually in target range, which is almost impossible to do if you're leveraging sliding scale.
And then we had a really great study come out of Brady, where they were able to show a 99.8% reduction in frequency of severe hypo. So basically making severe hypoglycemia, uh, a never. From a cost saving standpoint, this was a case study that KAA Delta did. They're actually, um, located in California. I think they're right around [00:24:00] a 500 bed hospital.
Uh, but they were able to reduce their hypoglycemia by 71%. They reduced their hyperglycemia by 33%. They were able to experience a 24% reduction in their average length of stay. And when they went back and mapped these clinical improvements back to what it meant from a cost savings standpoint, they were actually able to realize over 9 million in savings on an annual basis.
And then lastly, just from a, a time saving and an efficiency standpoint, we've seen, you know, huge, uh, increases in efficiency for clinicians. We've seen 30 minutes saved per prescriber per shift. Um, we, uh, regularly get very high, um, satisfaction, uh, rankings from clinicians who our technology. And then we also see a huge time savings for nurses who are obviously tasked with, you know, starting patients on insulin therapy and then, you know, kind of managing through the whole process.
And we've got a couple of really great quotes here [00:25:00] that I love to share. But, um, Dr. B from advent, you know, he actually, uh, admits he was one of our biggest, uh, opponents before they started using Glucommander. Um, but then once we got Glucommander in and he saw the benefits. It provided not only his patients, but also how it made clinicians' lives easier.
He admits to, you know, becoming obviously our, our biggest proponent. Um, and then we also got a really great, great quote from Deborah Duley, also from admin, where she said that they had more than a 75% reduction in first time calls to providers to change eGlycemic management, which is really just a, a huge win-win for, for a lot of folks.
Uh, you. Providers are no longer receiving calls at every hour of the night and, and, you know, nurses aren't having to make those calls. So, uh, it really is a, a huge benefit for, uh, for all of the clinicians and, and folks involved from a, a time saving standpoint. So at this point, um, that is really everything that I wanted to touch on.
So I'm gonna [00:26:00] hand it over to Johna to kick us off for the demo Johna.
Jonda: Thank you, Andy. My name is John Dawson. I'm a registered nurse and certified diabetes educator. As John mentioned before, most of my nursing career of 30 years has involved working with patients with diabetes. I am thrilled to have the opportunity to show you Glytec EEG S and Glucommander.
And I wanna thank you for taking the time to join us today. In the four and a half years, I've been a part of the Glytec team. I've guided over 20 of our partners through the implementation and delivery process. The hospital I worked at before joining my team was a Glytec partner. So I've been on your side of the table and I know firsthand how much of a difference Glucommander makes in improving the clinical workflows and guiding best practices and how that translates in optimal patient safety, which is our number one concern.
For today's demo. I'll be the nurse assigned to our patient. Matt Fitzgerald. [00:27:00] Matt is living with type one diabetes. And Dr. Beckley is his attending provider. Mac has been admitted to the hospital with a diagnosis of DKA. So Dr. Beckley has initiated the DKA order set, which includes Glucommander IV for insulin titration.
And Dr. Jones has verified the order I'm at Max's bedside. So I will open Max's patient record in the EMR and using our smart click integration button with one click I can access. Without having to leave the EMR after clicking on the Glucommander button, the IV initial order set page will load on the screen.
So Andy, I can take over the screen share.
With our order set initiation integration. The parameters of Glucommander order by Dr. Becksley will be automatically populated within this initial order set screen. This will ensure safety and efficiency and starting Mac on Glucommander [00:28:00] IV. If you look to the left, you can see we have an order set. We have our ADT integration, its pulled in all the max demographics and our lab integration has pulled over his current A1C on the right.
We have the parameters that Dr. Beckley has ordered for max Fitzgerald to be initiated on Glucommander IV. As max nurse, I verified these orders are correct. Next I will take appointed care of blood glucose. And my, my glucose meter reads high because max blood glucose is over the readable limit of our glucose meter commander's meter.
Max feature is one of the mini safety features in Glucommander Glucommander is configure to insert my hospital's glucose minimum or maximum button. The button automatically fills in the meter limit and allows me to proceed with treatment without having to wait for that actual lab value result for the main laboratory max insulin therapy will be started [00:29:00] immediately and without delay Glucommander will now give me any messages I need to review that guide best practice.
Glucommander will also recommend the initial infusion rate. Remember, this is the initial infusion rate rates will now be adjusted depending on how Mac is reacting to his insulin. Drip. I would go to my insulin pump program, my 5.4 units per hour and acknowledge I've done. So in Glucommander. Glucommander will now start the countdown from max next blood glucose check, which will be in one hour and Glucommander will remind me that the time has elapsed.
Once max blood glucose is within the order target range for at least two and a half hours. His blood glucose checks will then be every two hours. Now Mac has been on Glucommander IV for several hours. His blood glucose values have safely come down and stabilized within his order. Target range. Dr.
Beckley has determined. Mac is now ready to be [00:30:00] transitioned to Glucommander SubQ and has placed orders. Transition orders for my patient to transition to SubQ. After receiving the transition orders as nurse, I will click on the transition to SubQ button to start the transition process.
Dr. Besley's transition orders will autopopulate with our order set initiation integration as max nurse, I will verify these are correct and continue. Glucommander will guide me through the process. Step by step. The transition basal dose will now display along with a warning to not discontinue max IV insulin.
This ensures that Mac is safely bridged from IV to SubQ insulin therapy. Our blood glucose phase has pulled over a current point of care value of one milligrams per deciliter. Glucommander will now prompt me for [00:31:00] hourly blood glucose checks and will alert me when max insulin should be dis discontinued.
I converted SubQ banner now displays on max patient detail screen. This will be the last blood glucose check ending the transition process.
Glucommander will inform me to discontinue max insulin fusion rate. I can print the SubQ transition recommendations if. Now Mac has fully transitioned to a SubQ insulin patient. The transition process facilitated by Glucommander will help Mac avoid rebound hyperglycemia on the SubQ patient detail screen.
I can see max current basal and it's lunchtime and max tray has been delivered to his bedside. Our blood glucose interface will follow over our current blood glucose value. It resulted in the previous 45 [00:32:00] minutes, or I can manually enter the blood glucose value. I'm going manually enter a one 30 milligram deciliter blood glucose value.
Dr. Beckley has ordered a 60 carbohydrate from act and max thinks he's starving. He'll eat percent of his.
Now Glucommander will recommend how much insulin is needed to cover. Max Glucommander has recommended seven units of Humalog to cover the 60 grams for max lunch, since Mac was appropriately transitioned within Glucommander to subcu insulin, his glucose is in the order range. So no correction insulin has been recommended at this.
Glucommander automatically sends new dose recommendations to MYR. After I click on the save button, when I measure the dose and confirm it in the, the confirmation is automatically sent to [00:33:00] Glucommander via the integration, which closes the data loop Glucommander will measure the effectiveness and max administered insulin doses and recalculate future insulin doses to achieve prescribed by CME target.
With the help of Glucommander Dr. Beckley and I have helped resolve Mac Fitzgerald's decay safely and quickly with Glucommander IV and then transition from Glucommander SubQ. We can now safely transition him to a step down unit and open up that ICU bed for another patient. The guidance provides has helped me consistently follow best practice workflows.
Max insulin therapy has been personalized and adjusted to needs eliminating for glycemic excursions and insulin dosing changes. As you can see, EGMS will revolutionize your glycemic management program and in a variety of. [00:34:00] And it will be important to track the results. That's where comes in is a complimentary suite of analytics available to all of our tech partners that makes it easy to track.
Measure and share data dashboards throughout your organization. Having data is key in demonstrating to leadership. The value you'll realize through our EGMS software, it will demonstrate where you are succeeding and where there may be opportunities for optimization. It will also be instrumental in preparing for those new CMS measures.
We mentioned earlier, if you're interested in learning more about Glu or seeing a demo of the D. Please make sure to let us know and we'd be happy to schedule additional time. John I'll now turn things over to you. Our chief commercial officer, who will share a bit more about Glytec and CPS can work together.
John, you have the
John: thank you, John. I appreciate [00:35:00] it. Um, before we wrap up our time together today, I wanted to share a little bit about what it looks like when we initially engage with new customers. Um, We will come to the table with everything the customer needs to succeed. When we kick off a project, we typically start with our clinical and technical leads, sitting down with key stakeholders and making sure with a good understanding of what their needs are, what their goals are as well as what resources they have available.
And that's usually the key stakeholders are multidisciplinary team. Um,
Andy O'Dell: then we base on, you know, what we hear,
John: we'll customize a, a training and education plan specifically. For the customer that will guide them along the process. And as customers move forward from planning and they get deeper into the implementation phase, all the way to go live, we're there every step of the way to answer questions, address concerns, and provide assistance that, uh, our customers need.
Once the customer goes live. We stay involved customers entering what we call an [00:36:00] optimization phase, where we'll work closely with them to make any slight adjustments or tweaks to the system to ensure they're getting the level of benefit you'd expect to get outta Glucommander. Um, and after there's a go live and this optimization is complete, we, uh, transition the customer to our robust clinical customer success team.
So all of our clients are assigned a dedicated clinical customer success representative. Who are there to assist with anything Glucommander, you know, and during non-business hours, we actually do provide 24 7, 365 support. So if there are clinical or technical questions that come up, we're always here to provide, uh, support whenever our clients need it.
We also regularly push out product enhancements. So as we continue to invest in that technology, we ensure that our partners have the latest functionality, you know, that will include as Andy alluded to, you know, any kind of CGM integrations, any of our other integrations that we're working on with different partners on the screen [00:37:00] too, to point out, you'll see Paul ad talk's picture.
Paul's been instrumental in bringing our organizations together from the Glytec perspective. If you have any questions about Glytec feel free to reach out to. Finally, we have a great group of, of thought leaders within the Glytec family. Um, last year we initiated an industry conference time to target that brings were brought people together from, within the industry, both current Glytec partners and those who aren't yet partners for.
Free virtual conference around eGlycemic innovation and collaboration. The inaugural time, the target had nearly 750 registrants. We're very proud of the conference. So I'm gonna turn it over to Stephanie. She'll give you a little bit more about what will you know, what to expect during this year's conference.
Stephanie Mason: Yeah. Thank you, John. Um, yes, as, as John just said, we have our second annual time to target conference. This October, it's a virtual conference and it's free to register. The conference will be October 25th and 26th. And the theme for this year is the [00:38:00] future of glycemic management. And I will be doing a presentation as well as leading a pharmacy panel as part of the conference, uh, this year.
And so we'd love to see you in October. Uh, you can scan the QR code to get more information about the conference and also to. And with that, I think we'll move into our Q and a. I know we've been getting a lot of great questions and so we will we'll get started with those. And Andy, it looks like the first question is for you from Holly.
Do you integrate with epic? What about C.
Andy O'Dell: Uh, yes. So, so we do, we, we integrate with epic. We integrate with Cerner and, and really, uh, all of the, the EHRs that are in the market. So, um, you know, we've got a very robust, um, technical integration [00:39:00] team. That's got a lot of experience, um, you know, working in numerous, um, EHR environments and, and, and managing, um, pretty large complex integration projects.
So, so we. We're um, you know, very able and, and, um, open to, to integrating with, with pretty much anything that's in the market.
Stephanie Mason: Great. Thank you, Andy. Our next question is for Johna from Tony. Can you customize the treatments and target ranges based on my hospital's unique policy.
Jonda: Absolutely Glucommander is a customizable provider driven application. And what that means is you will be assigned a clinical project lead and they will begin to customize Glucommander to your facility.
So they will look at your current state insulin orders, your DKA protocols, and we will just want to embed Glucommander into [00:40:00] your order. There are four target ranges and there multipliers go from 0.01 to 0.05. And what we have is a breast practice document that matches up those two parameters. What we've seen works best in those populations.
So each unit can have their own parameters.
Stephanie Mason: you Janda. Let's see. Our next question is for Andy as well. And this is coming from Len does Glytec integrate with older EMRs, such as Meditech and Paragon.
Andy O'Dell: Uh, yes. Yeah, we, we, we integrate with them as well. Um, so there, there shouldn't be any, uh, any limitations there. Um, you know, we always like to do a little due diligence because, um, sometimes folks with some of the older, uh, older EHRs can, um, have some things that are kind of unique to their organization in terms of how they're set [00:41:00] up.
But, um, we have yet to come across a situation where we weren't able to integrate. So, so I would say yes to that. Uh, as well.
Stephanie Mason: great. Our next question here is for John, from Beth, how is Glucommander different from the epic insulin calculator?
John: Yeah, I mean, Glucommander, it's interesting and this is all we do. I, I think for us, you. If you can hopefully glean from the presentation. You know, our team is really we're. We are really just around glycemic management.
Um, you know, our algorithm is, is one that with the rapper of Glucommander at EGMS, um, you know, we have the full FDA clearances, so we're covering the full continuum of care. You know, I think it's personalized insulin dosing. Whereas we understand that the epic calculator is really, um, a [00:42:00] static lookup. Um, you know, it's, it's a calculator, but it's kind of a one size fits all approach.
So I think from those perspectives, you know, having the comfort of the FDA clearance, which I know Andy touched on, um, and the other piece in there, I mean, you know, it's coming fast, right. Is, uh, the CMS core measures and CGM. And so I think for CGM usage, Um, right now from our understanding of being part of, uh, an industry standards, um, kind of collective called I code, you know, that we're working in conjunction with epic, with Cerner, with other major players in the space.
You know, we understand that, um, Really the CGM manufacturers do not have the software capability to integrate with EMRs and EMRs, you know, right now are I think not concentrating on how they're gonna integrate with CGM. So I think they're both entities are looking to, um, to Glytec to be that middleware.
So I think we're excited about what's coming on the future, but, um, I think it's a mistake for, you know, for entities, [00:43:00] just to believe that the, you know, the, the calculator within epic. Is gonna solve your problem. It's still gonna take it resourcing to do updates. It's it's not as, probably as easy as everybody makes it out to be.
Um, and I think there's hidden costs there as well. So, um, those are all comments we love. Be happy to follow up offline about.
Stephanie Mason: Great. Thank you, John. And let's see our, our last question here is for Johna from Len. Um, sometimes patients respond differently and even with the most diligent care, some patients still have hypoglycemia in facilities that use Glucommander. What is the average hypoglycemia rate? Good
Jonda: question Lynn and you arrive all patients react differently, but with Glucommander the hypoglycemic events are almost never event.
We have studies that show that hypoglycemia with our [00:44:00] Glucommander IV can decrease hypoglycemic events between 90 and 99%. That is just huge. For our hypoglycemic events with safety features like we saw at meter max, we also have a glucose velocity that helps us with those patients that their blood glucose is decreasing rapidly.
We have a built-in trigger. It pumps the breaks looks at that patient's blood glucose a little bit more frequently. And also we treat hypoglycemic. With a customized dose of D 50, all of that together helps us make those hypoglycemic events, almost a never event, which is what CMS is looking for.
Stephanie Mason: All right. Thank you, Jonda. It looks like that is all the time that we have today. Uh, but if you think of anything after we wrap up, please feel free to reach out to my colleague, Paul Adcox. Uh, his information is, um, on the slide here. [00:45:00] If you'd like to schedule a more personalized presentation or demo to go into more details, uh, please reach out to Paul.
He'd be happy to do that, um, as well, but on behalf of John Jonda, Andy and myself, uh, thank you everyone for your time today. And we hope you enjoy the rest of your day.
Jonda: Thank you everyone.